Nucleic Acid Amplification Testing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Nucleic Acid Amplification Testing Market: By Technique (Target amplification systems, Probe amplification systems, and Signal amplification), By Application (Infectious Diseases (Viruses, Bacteria, and Others), Cancer, Personalized Medicine, and Genetic and Mitochondrial Disorders), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Nucleic Acid Amplification Testing Market size is expected to be worth USD 1,951.4 million in 2022, growing at a high CAGR of 9.4% from 2022 to 2028 to reach USD 3,336.2 million by 2028. In 2021, Signal amplification systems had a market revenue share of 21.3%, and from 2022 to 2028, it is predicted to increase at a CAGR of 9.5%. One advantage of signal amplification systems is that they provide more options for target recognition sequences in some circumstances. The increased prevalence of infectious diseases, the rising need for better diagnostic measures, and rising investment in developing new biotechnological diagnostic procedures are driving the Nucleic Acid Amplification Testing market. Furthermore, nucleic acid amplification testing delivers the most exact detection. It is thus frequently preferred over older methods, owing to the growing need for improved testing methods and the biopharmaceutical industry’s increased R&D expenditure.  However, the lack of skilled professionals and high costs hampers the nucleic acid amplification testing market. For COVID-19 (SARS-CoV-2), a Nucleic Acid Amplification Test (NAAT) is a form of a viral diagnostic test. NAATs are genetic material detectors (nucleic acids). SARS-CoV-2 NAATs identify the RNA (ribonucleic acid) sequences that make up the virus’s genetic material.

Key Developments:

In January 2021, Xpert Xpress SARS-CoV-2 of Cepheid was launched for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens.

Nucleic Acid Amplification Testing Market

MARKET SUMMARY
-
9.4%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.4%
  • Largest Market– Asia Pacific
  • Fastest Growing Market–  North America

Nucleic Acid Amplification Testing Market

  • The nucleic acid amplification testing market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The nucleic acid amplification testing market is segmented based on based on technique, application, and geography.
Key Players
  • Hoffmann-La Roche
  • Becton
  • Dickinson and Company
  • Beckman Coulter
  • Abbott Laboratories
Nucleic Acid Amplification Testing Market Dynamics

Nucleic Acid Amplification Testing market is surging owing to frequent acquisitions and launchings by the market players. Strategic alliances by the players such as acquisitions, mergers, expansions, and new product launches may enhance the company’s growth. For instance, In March 2020, Abbott launched Abbott’s point-of-care ID NOW platform, a molecular point-of-care test to detect novel coronavirus in as little as five minutes


North-America Got Significant Share

Nucleic Acid Amplification Testing Market

North America is predicted to have the largest share of the Nucleic Acid Amplification Testing market by 2027, and it is expected to grow at a rapid pace in the following years. Because of improved healthcare infrastructure and the increased prevalence of infectious diseases, the United States is predicted to be the largest nucleic acid amplification testing market. NAAT was deployed in Canada by the Canadian Blood Services, and it is helping to ensure a safer blood supply by detecting tiny quantities of viral genetic material.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The nucleic acid amplification testing market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Nucleic Acid Amplification Testing Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The nucleic acid amplification testing market is projected to expand at a CAGR of 9.4% during the forecast period.

Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers

North America is dominating the nucleic acid amplification testing market


Report

Company Profile

  • Hoffmann-La Roche
  • Becton
  • Dickinson and Company
  • Beckman Coulter
  • Abbott Laboratories
  • Illumina
  • Siemens Healthineers
  • bioMerieux
  • Novartis
  • Bio-Rad Laboratories

Description

Nucleic Acid Amplification Testing Market size is expected to be worth USD 1,951.4 million in 2022, growing at a high CAGR of 9.4% from 2022 to 2028 to reach USD 3,336.2 million by 2028. In 2021, Signal amplification systems had a market revenue share of 21.3%, and from 2022 to 2028, it is predicted to increase at a CAGR of 9.5%. One advantage of signal amplification systems is that they provide more options for target recognition sequences in some circumstances. The increased prevalence of infectious diseases, the rising need for better diagnostic measures, and rising investment in developing new biotechnological diagnostic procedures are driving the Nucleic Acid Amplification Testing market. Furthermore, nucleic acid amplification testing delivers the most exact detection. It is thus frequently preferred over older methods, owing to the growing need for improved testing methods and the biopharmaceutical industry’s increased R&D expenditure.  However, the lack of skilled professionals and high costs hampers the nucleic acid amplification testing market. For COVID-19 (SARS-CoV-2), a Nucleic Acid Amplification Test (NAAT) is a form of a viral diagnostic test. NAATs are genetic material detectors (nucleic acids). SARS-CoV-2 NAATs identify the RNA (ribonucleic acid) sequences that make up the virus’s genetic material.

Key Developments:

In January 2021, Xpert Xpress SARS-CoV-2 of Cepheid was launched for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX